Paratek Pharmaceuticals (NasdaqGM: PRTK) is a biotechnology company developing novel antibiotics to combat the rise of bacterial resistance. The Company’s lead compound, omadacycline, has been shown to have broad spectrum activity against a wide range of clinically-relevant bacteria including key drug-resistant strains. Paratek is developing omadacycline as a treatment for acute skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and also intends to pursue an indication for complicated urinary tract infections (cUTI) in the future. Following positive results in a Phase II trial evaluating omadacycline in ABSSSI patients, Paratek plans to launch two Phase III trials for the treatment of ABSSSI and CABP in the middle of 2015.

Read More